ArticleMedical oncology (Northwood, London, England)2025
Mechanism of Dahuang-Dangshen drug pairs in the treatment of HCC based on network pharmacology, bioinformatics, molecular docking and experimental verification.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Processing enhances the anti-hepatocellular carcinoma effect of Momordicae Semen via remodeling chemical composition and regulating the Akt/mTOR/STAT3 pathway.Biochemistry and biophysics reports · 2026Article
- Natural Plant Bioactives as Regulators of Histone Modifications: Bridging Epigenetics and Anticancer Therapy.Phytotherapy research : PTR · 2026Review
- How Traditional Chinese Medicine Works: Biological Mechanisms and Clinical Evidence for Hepatocellular Carcinoma Treatment.Drug design, development and therapy · 2026Review
- Ginkgo biloba extract suppresses hepatocellular carcinoma progression by inhibiting the recruitment of myeloid-derived suppressor cells through reduced CXCL1 secretion via SRC downregulation.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The anti-hepatocellular carcinoma (HCC) effect of the active ingredients of natural Chinese herbal medicine has become a hot topic at home and abroad. A list of studies evidence the therapeutic efficacy of Dahuang (DH) or Dangshen (DS) against HCC, but the combination effect of DH and DS in HCC treatment is rarely reported and the molecular mechanism of the drug pairs is not yet clear. Therefore, in this study, the combined effects and potential mechanisms of DH and DS drug pairs were investigated through network pharmacology, bioinformatics, molecular docking, and a series of pharmacological experiments, including the MTT assay, clone formation, wound healing, JC-1 staining, and western blotting. In total, 140 intersection targets between the DH-DS drug pairs and HCC were identified. In the PPI network, the top ten hub targets with the highest node connection values were VEGFA, AKT, CTNNB1, EGFR, TNF, CASP3, HRAS, SRC, JUN, and ESR1. GO functional and KEGG pathway enrichment analysis involved 289 biological processes, 33 cellular components, 57 molecular functions, and 143 signaling pathways. Bioinformatic analysis indicated that EGFR and AKT were promising candidate genes that can serve as diagnostic and prognostic biomarkers for HCC. β-sitosterol from the DH drug and luteolin from the DS drug were found as promising small molecules for HCC. The experimental results showed that the combination of β-sitosterol and luteolin was more potent in suppressing cell proliferation, migration and inducing cell apoptosis when compared to β-sitosterol or luteolin alone. The western blot and molecular docking studies demonstrated that the potential mechanism may be related to the EGFR/AKT signaling pathway. In summary, the combination of DH and DS may resist cell proliferation, migration and promote apoptosis activity through the EGFR/AKT signaling pathway, which provides new insights for further exploring plant extract treatment for HCC.
Indexed as
Identifiers
40261593What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.